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Although it has been known for more than a century
that digitalis glycosidesexert a powerful beneficialeffect
on patients with heart failure, atrial fibrillation and a
rapid ventricular rate, it was believed for many years
that the drug exerts this clinical effect primarily by slow-
ing the heart rate. It was also thought that the extra-
cardiac vascular actions of digitalis might be responsible
for its therapeutic effect. It has now been established
that cardiac glycosidescause arteriolar and venous con-
striction in a variety of mammalian species including
human beings, and that this vasoconstriction involves
the coronary vascular bed as well, but it is believed that
these actions are not responsible for any beneficialclin-
ical effect. A variety of investigations on cardiac muscle
in vitro, anesthetized and conscious dogs and anesthe-
tized and conscious human subjects have shown that
cardiac glycosides improve the contractility of failing
mammalian myocardium. It has become clear that dig-
italis also stimulates the contractility of the nonfailing
heart. The degree of augmentation of contractility in-
duced by cardiac glycosides is related inversely to the
baseline contractile state. Myocardial oxygen consump-
tion, which is increased in the normal heart by the pos-
itive inotropic action of glycosides, is actually reduced
or remains constant in the failing heart. Cardiac gly-
cosides increase the contractility of the globally ischemic
William Withering (1) was well aware that digitalis is ef-
fective only in certain forms of dropsy , but because edema
had not been clearly identified as a cardinal manifestation
of heart failure two centuries ago, he did not associate this
clinical effect with the cardiac actions of the drug. However,
Withering did recognize that the drug causes an improve-
ment in the pulse, and he stated that digitalis " has a power
over the motion of the heart with a degree yet unobserved
in any other medicine" (1) . Fourteen years later, John Fer-
riar correctly ascribed a primary effect of digitalis on the
heart and assigned secondary importance to its diuretic ac-
tions (2). Subsequently , on the basis of auscultatory studies,
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heart, but their actions in chronic ischemic heart disease
with regional impairment of function are complex. De-
terioration of segmental performance occurs in ischemic
and necrotic segments, while improvement of contrac-
tility occurs in adjacent normal segments. A modest im-
provement in left ventricular pump performance occurs
in patients with chronic ischemic heart disease with im-
pairment of global left ventricular function.
There has been considerable debate concerning the
clinical value of digitalis therapy in heart failure. Simple
withdrawal of digitalis resulted in no clinical deterio-
ration in many patients with mild to moderate heart
failure. However, in patients with more severe impair-
ment of cardiac function, aggravation of heart failure
occurred after digitalis withdrawal, and striking clinical
improvement was noted when the drug was readminis-
teredo Thus, cardiac glycosidesare relatively weak ino-
tropic agents, have a low therapeutic ratio and are mod-
erately effectivein heart failure secondary to ventricular
volume overload. However, when properly used in pa-
tients with severe heart failure and sinus rhythm, par-
ticularly in patients with atrial fibrillation, cardiac gly-
cosides improve both cardiac performance and the clinical
state and can be administered effectively for years.
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Bouillard (3) reported that a rapid and irregular pulse was
improved by digitalis, which he considered to be "opium"
for the heart. By the latter half of the 19th century , it was
well recognized that digitalis enhances ventricular contrac-
tion (4). It had also become clear that digitalis glycosides
exert a powerful beneficial clinical effect on patients with
heart failure who had atrial fibrillation and a rapid ventricular
rate, but it was believed that the drug exerted its clinical
effect in such patients primarily by slowing the heart rate.
Actions on the Vascular Bed
Normal subjects. Early in this century it was suggested
that a principal circulatory action of digitalis might be ex-
tracardiac, and that the direct effects of the drug on the
vascular bed might be mainly responsible for its therapeutic
action (5). More recently it was established that cardiac
glycosides do exert a distinct direct action on the vascular
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bed; they cause arteriolar and venous constriction in anes-
thetizeddogs (6,7) and human subjects (8) (Fig. l) as well
as in conscious normal humansubjects (9). In the conscious
dog ouabaincauses markedelevationof coronary and total
systemic vascular resistance (10). Although cardiac gly-
cosides have a local direct action on vascularsmooth mus-
cle, they also act indirectly by causing neurogenically me-
diated coronary vasoconstriction (2).
Patients with heart failure. In patients withcongestive
heart failure, baseline levels of total cardiac output and
forearm blood flow are lower, whereas total and forearm
vascularresistances and venous tone are higher than in nor-
mal subjects (9). In such patients, the effect of ouabainon
the vascular bed is directionally opposite to that observed
in normal subjects; that is, it causes reductions of total
systemic forearm vascular resistance and forearm venous
tone (9). It is likelythat thesevasodilator actionsare indirect
and result from the reduction of reflex sympathetically me-
diated arteriolar and venoconstriction that occurs as a con-
sequenceof the elevationof cardiac output induced by dig-
italis in patients with heart failure.
It now appears that rather than being responsible for the
beneficial effects of these drugs, the systemic and coronary
vascularconstriction producedby rapidlyacting glycosides
givenintravenously mayactually be responsible fora variety
of complications (11,12) including acute exacerbation of
heart failure. The vasoconstrictor effect of digitalis has a
morerapidonset than its inotropic action(8). Thus, to avoid
systemic and coronaryvasoconstriction whenrapidly acting
glycosides are indicated, intravenous administration as a
bolus should generally be avoided, particularly in patients
with ischemic heart disease.
Figure 1. Recording of brachial artery pressure in a 27 year old
woman during repair of an atrial septal defect using cardiopul-
monary bypass at a constant systemic perfusion rate. Arterial pres-
sure, which at a constant perfusion rate reflects systemic vascular
resistance, begins to increase 20 seconds after the injection of
acetylstrophanthidin. Seven minutes after injection the pressure
has already fallen, and 12 minutes after injection it is only slightly
higher than the control level. (Reproduced with permission from
Braunwald E, Bloodwell RD, Goldberg LI, Morrow AG. Studies
on digitalis. IV. Observations in man on the effects of digitalis
preparations on the contractility of the non-failing heart and on
total vascular resistance. J Clin Invest 1961;40:52-9.)
Effects on the Failing Heart
Atrial fibrillation versus sinus rhythm. It is now be-
yond dispute that the digitalis glycosides display efficacy,
both immediately and over the long term, in the control of
heart failure and ventricular rate in patients with atrial fi-
brillation, Indeed, the development of an increase in atrio-
ventricular block resulting in slowing of an excessive ven-
tricular rate remains a principal indication for the use of
digitalis (13). However, Christian (14) and other investi-
gators suggested early in this century that this drug may
also be effective in the treatment of patients with heart
failure and sinus rhythm. Although cardiac glycosides are
still advocated as the principal inotropic agents for the treat-
mentof heartfailure (13), and although studiesofthe effects
of their short-term administration to patientshaveconfirmed
that they improve myocardial performance in patients with
heartfailure and sinusrhythm(15), thereis stillconsiderable
controversy about whether patients with sinus rhythm who
receive maintenance therapyderive clinicalbenefit (16). To
understand thiscontroversy, it is necessary to reviewseveral
aspects of the action of this drug.
Inotropic action of digitalis. The modem era of digi-
talis pharmacology began in 1940 when Gold and Cattell
(17) demonstrated that digitalis increases the contractility
of failing isolated cat papillary muscle in a dose-dependent
manner (Fig. '-). Subsequently, it was shown that digitalis
also improves the function of the failing heart-lung prepa-
ration of the dog (18). It is now clear that the extent of the
positive inotropic action of the drug is related inversely to
the baseline condition of the myocardium, cardiac muscle
with depressed function showinga more vigorous response
to the glycoside than normally contracting myocardium.
These observations on the direct positive inotropic ac-
tions of cardiac glycosides have been extended to human
subjects, and it has been demonstrated (19) that the con-
tractility of papillary muscle removed from patients with
heart failure, as reflected in the time-tension and force-
velocity relations, is enhanced by the addition of strophan-
thidin(Fig. 3). Hemodynamic studies(2,13,15) haveshown
that when glycosides are administered to patients with heart
failure, they elevate the ventricular function curve, causing
a reduction in ventricular end-diastolic pressureand volume
and an augmentation of cardiac output and stroke work.
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Figure 2. The effect of ouabain on force of contraction of an
isolated papillary muscle from the right ventricle of a cat heart.
(Reproduced from [17) with permission.)
Effects on the Nonfailing Heart
While there is now general agreement regarding the pos-
itive inotropic effect of digitalis in the failing heart, there
has been considerable dispute concerning its actions on the
normal heart and the nonfailing though diseased heart. Dig-
italis does not increase the cardiac output at rest or during
exercise in subjects without heart failure (20), but its cardiac
stimulating action is reflected in the finding that the same
levels of cardiac output and stroke work are delivered from
a lower ventricular filling pressure or during a shorter period
of time, or both. Several other lines of evidence indicate
that cardiac glycosides do indeed exert a positive inotropic
effect on nonfailing cardiac muscle. The effects of the long-
term administration of digitoxin on the contractile state of
nonfailing myocardium were studied in papillary muscles
obtained from normal cats and from cats in which ventricular
hypertrophy had been produced by banding of the pulmo-
nary artery (21). While the muscle's length-tension relations
at rest were not affected by the glycoside, the isometrically
developed force and the maximal rate of force development
were increased in both normal and nonfailing hypertrophied
myocardium.
Canine studies. In investigations on the conscious dog,
it was found that at similar heart rates and left ventricular
end-diastolic pressures, the long-term administration of di-
goxin increased left ventricular force, maximal rate of rise
of left ventricular pressure (dP/dt) and the velocity of myo-
cardial shortening (22). McRitchie and Vatner (23) also
showed that in normal conscious dogs ouabain increases
arterial pressure as well as indexes of myocardial contrac-
tility, such as left ventricular dP/dt divided by pressure
([dP/dt]/P) and the velocity of fiber shortening. The positive
inotropic effect of the drug was also reflected in its ability
to maintain stroke volume and to reduce left ventricular end-
systolic dimensions at a constant preload, despite an increase
in arterial pressure. However, in the intact heart of the
conscious dog (for example, in isolated cardiac muscle),
the degree of the augmentation of contractility induced by
cardiac glycosides is related inversely to the baseline con-
tractile state. Thus, in the normal conscious dog, when
myocardial contractility is stimulated by adrenergic activity,
as occurs during exercise, cardiac glycosides exert only a
negligible positive inotropic effect (24). Conversely, the
inotropic effects of glycosides are more prominent in the
failing than in the nonfailing heart; the effects of ouabain
on right ventricular segment length, pressure, velocity of
shortening and (dP/dt)/P were studied in conscious dogs
before and after the induction of chronic right heart failure
(25). Although ouabain exerted an inotropic effect in normal
healthy, conscious dogs, this effect was substantially greater
in the presence of chronic heart failure (Fig. 4). Similarly,
acute depression of myocardial function in the normal dog
induced by sodium pentobarbital or large doses of propran-
olol enhanced the inotropic effects of ouabain (Fig. 5) (26).
There is also evidence that cardiac glycosides elevate the
performance of the canine heart when the latter is depressed
by halothane (27) or thiopental (28) and reduce the oxygen
debt after exercise in patients with cardiac enlargement but
without heart failure (29).
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Figure 3. The effect of the addition of strophanthidin on the force-
velocity relation of a human left ventricular papillary muscle stud-
ied in vitro. The addition of strophanthidin increased both Vmax
and Po (the maximal force of isometric contraction, that is, in-
tercept on the abscissa), while decreasing the time from stimulation
to maximal shortening from 390 to 340 ms. (Reproduced with
permission from Sonnenblick EH, Braunwald E, Morrow AG.
Contractile properties of human heart muscle: studies on myo-
cardial mechanics of surgically excised papillary muscles. J Clin
Invest 1965;44:966-77.)
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Figure 6. Right ventricular contractile force recordings immedi-
ately before and at intervals after the administration of 1.5 mg of
acetylstrophanthidin in a 27 year old woman with atrial septal
defect (same patient as in Fig. I). Augmentation of contractile
force is evident 3 minutes after injection. (Reproduced with per-
mission from Braunwald E, Bloodwell RD, Goldberg LI, Morrow
AG. Studies on digitalis . IV. Observations in man on the effects
of digitalis preparations on the contractility of thenon-failing heart
and on total vascular resistance. J Clin Invest 1961;40:52-9.)
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prompt increase in isometric force development, indicating
that the digitalis glycosides do stimulate the nonfailing heart
of anesthetized human patients (Fig. 6). These studies were
then extended to' conscious human subjects without heart
failure in whom the measurement of maximal dP/dt was
recorded using a high fidelity rnicromanometer catheter;
ouabain increased both right and left ventricular dP/dt (Fig.
7) (30).
The results of several additional studies on the action of
cardiac glycosides on nonfailing human myocardium are in
accord wiith these findings. Thus. the effects of ouabain on
ventricular force-velocity relations were studied in con-
scious patients without heart failure who had previously
undergone corrective cardiac operations, at which time
radiopaque markers had been sewn to the external surfaces
of the ventricle (31). The glycoside augmented myocardial
contractility, simultaneously increasing velocity of short-
ening and intraventricular pressure (Fig. 8). Crawford et at.
(32) examined the effects of digoxin on left ventricular
function in normal subjects using echocardiography. They
observed a positive inotropic action, as reflected in an in-
crease in the left ventricular ejection fraction and an aug-
mentation of the extent and rate of left ventricular shortening
as well as significant improvement in left ventricular per-
formance after acute pressure loading.
The observations just summarized indicate quite clearly
that digitalis glycosides stimulate the contractility of the
nonfailing human heart. However , these drugs do not affect
cardiac output at rest or maximal levels of oxygen uptake,
pulmonary ventilation or heart rate in normal subjects (20) .
Therefore, adjustments of the other determinants of cardiac
output, such as preload, afterload and heart rate, prevent
this increase in contractility from being translated into an
augmentation of cardiac output (33). There is no evidence
that the administration of digitalis is of any clinical value
in patients with sinus rhythm without heart failure and its
administration prophylactically to such patients is not or-
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Figure 4. Comparison of the effects of ouabain in the same con-
scious dog before (triangles) and after (circles) congestive heart
failure (CHF) had been induced. Not only was the peak effect
greater but the positive inotropic action of the drug was more
sustained in the failing heart. Baseline measurements are shown
at the left. VISO = velocity of shortening at the same length
(isolength). (Reproduced with permission of the American Heart
Association, Inc. from VatnerSF, BraunwaldE. Effectsofchronic
heart failure on the inotropic response of the right ventricle of the
conscious dog to a cardiac glycoside and tachycardia. Circulation
1974;50:728-34.)
Human studies. The effects of digitalis on the force of
contraction of the nonfailing human heart were studied using
a force transducer sewn to the right ventricle of patients
without heart failure undergoing cardiopulmonary bypass
(8). Both acetylstrophanthidin and lanatoside C produced a
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Figure 5. The average (± SEM) values for the quotient of dP/dt
and developed left ventricular (LV) pressure, an index of myo-
cardial contractility, before and 30 minutes afterouabain for con-
sciousdogs (left panel), afteranesthesia (middle panel) andcon-
sciousdogsafter propranolol (rightpanel); thesmallest augmentation
occurs in the normal conscious dog (left panel). (Reproduced with
permission from Vatner SF, Higgins CB. Patrick T, Franklin D.
Braunwald E. Effects of cardiac depression and of anesthesia on
the myocardial action of a cardiac glycoside. J Clin Invest
1971;50:2585-95.)
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Figure 7. Recordings of left ventric-
ular (LV) pressure andrateof change
of pressure (dP/dt)before and30 min-
utes after ouabain administration in a
patient without heart failure . EKG =
electrocardiogram. (Reproduced with
permission from Mason OT. Braun-
wald E. Studies on digitalis. IX . Ef-
fects of ouabain on thenon-failing hu-
man heart . J Clin Invest 1963;
42: 1105-11 .)
Figure 8. The effects of ouabain on the instantaneous force-ve-
locity relations of the right ventricle (R.V,) of a conscious human
subject with radiopaque markers implanted on the epicardium at
the time of corrective surgery . The velocity of shortening of the
segment of myocardium between themarkers at theisolength (ISL)
point isplotted ontheordinate. Thecorresponding right ventricular
pressure is plotted on the abscissa. Each point represents a single
ventricular contraction, and the crossbars represent ± I SO.
(Reproduced with permission of the American Heart Association .
Inc. from Sonnenblick EH , Williams JF Jr, Glick G, Mason OT.
Braunwald E. Studies on digitalis. XV. Effects of cardiac gly-
cosides on myocardial force-velocity relations in the non-failing
human heart . Circulation 1966;34:532-9.)
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Effects in Myocardial Ischemia and
Ischemic Heart Disease
Myocardial oxygen consumption (MVO z). To under-
stand the action of glycosides in myocardial ischemia and
ischemic heart disease, it is useful, first, to consider their
effects on MVOz. Because the MVOz is determined largely
by intramyocardial tension. myocardial contractility and heart
rate, the net action of digitalis on these three hemodynamic
variables governs its effect on MVOz (34) . In anesthetized
dogs without heart failure or cardiac dilation, digitalis aug-
ments myocardial contractility with little effect on intra-
myocardial tension and heart rate; therefore, it might be
expected to, and indeed it does, elevate MVOz in the non-
failing heart. However, in the presence of heart failure,
digitalis reduces ventricular volume and thereby intramy-
ocardial tension. Heart rate may also be slowed in heart
failure as a consequence of diminished sympathetic drive,
and these two effects tend to balance the increase in MVOz
resulting from augmented myocardial contractility; the net
effect is to produce either no change or a small increase in
MVOz (35). DeMots et al. (36) demonstrated in patients
with chronic ischemic heart disease without heart failure
that ouabain reduces left ventricular end-diastolic pressure
and volume and augments the maximal velocity of estimated
contractile element shortening; it causes no significant change
in MVOz, presumably because of the opposing effects of
the glycoside-induced reduction in tension and augmentation
of contractility.
Acute hypoxia, ischemia and infarction. There is con-
siderable evidence that digitalis glycosides are capable of
stimulating the acutely hypoxic or ischemic heart (37). Thus,
in dogs in which severe systemic hypoxia was induced by
respiring 7 to 10% oxygen, acetylstrophanthidin caused el-
evations of left ventricular dP/dt and stroke work that were
distinct but smaller than the changes induced by identical
doses of the drug in nonhypoxic animals (38). Similarly,
Sarnoff et al. (39) reported that the intracoronary injection
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controversial (37) . Thus , Cohn et al. (II) administered car-
diac glycosides intravenously to patients with cardiogenic
shock . They reported a short-term increase in systemic vas-
cular resistance that was associated with the development
of pulmonary edema in one patient. Later, there was an
increase in myocardial contractility, as reflected in an in-
crease in the left ventricular maximal dP/dt, usually accom-
panied by a decrease in the left ventricular end-diastolic
pressure; however, cardiac output was not increased sig-
nificantly . In patients with acute myocardial infarction and
congestive heart failure without cardiogenic shock, several
investigators (45,46) observed that digitalis increases ejec-
tion fraction slightly . Morrison et al. (47) also reported that
in patients with acute myocardial infarction, digoxin causes
a modest but significant elevation of a depressed ejection
fraction (from 0.29 to 0.33).
Chronic ischemic heart disease. Kleiman et al. (48,49)
studied the effects of both intravenous and oral digoxin in
patients with stable coronary artery disease without clinical
evidence of heart failure after coronary artery bypass graft-
ing. Using computer-assisted fluoroscopic analysis of the
motion of markers implanted into the myocardium at op-
eration, they observed that the ejection fraction and the
velocity of circumferential fiber shortening both increased,
while the left ventricular end-diastolic volume and cardiac
output did not change significantly. The improvement in
performance induced by digoxin was greater in normal myo-
cardial segments than in segments that were contracting
abnormally due to ischemia or fibrosis. Indeed, deterioration
of segmental performance occurred in approximately half
of the segments with depressed function, a deterioration that
may be due to the inability of infarcted segments of myo-
cardium to sustain the increased wall tension resulting from
the digitalis-induced augmented contractility of the normal
myocardium. Therefore, in patients with ischemic heart dis-
ease, the response of particular segments of the myocardium
to cardiac glycosides appears to depend on the relative quan-
tity of viable nonischemic muscle, on the one hand, and of
ischemic or infarcted muscle in the particular segment, on
the other. It has been suggested that it is the failure of
ischemic and necrotic segments of the myocardium to re-
spond to digitalis which is responsible for the lack of im-
pressive improvement of left ventricular function in patients
with acute myocardial infarction who are treated with the
drug (50).
In patients with chronic ischemic heart disease, the acute
administration of digoxin had a mild beneficial effect on
global left ventricular performance at rest, but did not alter
the onset of exercise-induced angina or affect exercise-
induced deterioration of left ventricular function (51) . Simi-
larly, Firth et al. (52) reported that digoxin did not cause
any significant change in left ventricular function at rest in
patients with ischemic heart disease. Although the glycoside
prevented the exercise-induced increases in left ventricularOUABAINc
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of acetylstrophanthidin into a globally ischemic isolated ca-
nine heart caused a marked improvement of cardiac con-
tractility. In the conscious dog with acute coronary occlu-
sion, ouabain improves global left ventricular performance
(40), and in the nonfailing dog heart cardiac glycosides
intensify the ischemia produced by coronary occlusion (41),
presumably by augmenting myocardial oxygen requirements.
However, in the failing heart, digitalis has the apposite
effect (42); by reducing myocardial oxygen requirements.
cardiac glycosides may reduce the severity 'of ischemia in-
duced by coronary occlusion (Fig. 9) .
The routine use of digitalis in the management of patients
with acute myocardial infarction was first suggested by Her-
rick in 1912 (43) and the drug was initially employed widely
in this condition (44). Subsequently, its use became more
Figure 9. Average effecIs (:!: SEM) of ouabain on mean ST
segment elevation and hemodynamic variables after coronary li-
gation and with arterial pressure increased in six anesthetized open
chest dogs with experimentally produced heart failure. There is
little effect on mean aortic pressure or heart rate . Ouabain caused
a striking decline of markedly elevated mean left atrial pressure ,
accompanied by a striking reduction of ST segment elevation of
the ischemic myocardium. (Reproduced with permission from Wa-
tanabe A, Covell JW. Maroko PR, Braunwald E, Ross J Jr. Effects
of increased arterial pressure and positive inotropic agents on the
severity of myocardial ischemia in the acutely depressed heart .
Am J Cardiol 1972;30:371-7.)
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end-diastolic and end-systolic volumes in patients with a
normalejection fraction at rest, it failed to do so in patients
with a depressed ejection fraction. Thus, the positive ino-
tropic effects of long-term digoxin therapy could be dem-
onstrated more readily in patients with chronic ischemic
heart disease whose left ventricular function was well pre-
served than in those with an extensive infarct. These ob-
servations support those of Kleiman et al. (48,49) and sug-
gest that theextent of improvement of left ventricular function
by glycosides in chronic ischemic heart disease without
overt heart failure depends on the relative quantitiesof well
preserved and extensively damaged myocardium.
In light of the foregoing data, there is little doubt that
cardiac glycosides can improve myocardial performance in
patients with ischemic heart disease. The degree of im-
provement, however, varies among different patients and
indifferentportionsof the ventriclein anyone patient.Thus,
glycosides cause no improvement or can even result in sys-
tolicexpansionof severelyischemic or scarredmyocardium.
They cause only slight augmentation of contractility in nor-
mal myocardium that is adrenergically stimulated because
of left ventricular failure as a consequence of extensive
ischemiaor infarction. Therefore, digitalis glycosides cause
only modest improvement of global left ventricular function
in heart failure occurring as a consequence of acute myo-
cardial infarction. Indeed, transient acute deterioration of
left ventricular function may occur when a rapidly acting
glycoside is administered intravenously and elevates sys-
temic vascular resistance and ventricular afterload acutely
in patients with heart failure secondary to ischemic heart
disease. Digitalis may cause a modest improvement of left
ventricularpump performance in patients with chronic isch-
emic heart disease and impairedglobal left ventricularfunc-
tion. However, the salutary effects of glycosides on left
ventricular pump function in such patients are less than in
patients with left ventricular failure secondary to chronic
ventricular volume overload, such as occurs in valvular
regurgitation.
Clinical Implications
Mulrow et al. (53) recently provided a critical appraisal
of the 16 articles published in English between 1960 and
1982 which specifically address the clinical evaluation of
digitalis therapy in heart failure. In the nine studies in which
the effects of simple withdrawal of digitalis therapy were
studied, no consistentevidence of clinical deterioration was
noted. However, because detailed criteria for patient selec-
tion were not provided in these studies, few conclusionscan
be drawn from them. In three other investigations, the ad-
ditionof digoxinwas not foundto haveany beneficial effects
over therapy with diuretic drugs alone. Arnold et al. (54)
foundthat left ventricularfunctiondeterioratedafter digitalis
withdrawal, whereas Gheorghiade and Beller (55), who
studied patients with chronic ischemic heart disease and
heart failure who were also treated with diuretic drugs and
vasodilators, reported that withdrawal of digoxin had no
adverse clinical or hemodynamic effects.
Murray et al, (56) reported that long-termtreatmentwith
digitalis in patients with sinus rhythm and symptomatic car-
diac failure caused little change in hemodynamic measure-
ments at rest, but did result in lower left ventricular end-
diastolic pressures and highercardiac indexand stroke work
during exercise. These changes were observed both after
the short-term administration of ouabain and long-term oral
digoxin therapy. Fleg et al. (57) carried out a placebo-
controlled crossover study with digoxin and reported that
the withdrawal of digitalis in patients with compensated
heart failure increased ventricular end-diastolic dimensions
and decreased the velocity of fiber shortening, but did not
cause a clinical exacerbation of heart failure. They con-
cluded that the drug is of little benefit in elderly patients
with stable congestive heart failure, because none mani-
fested deterioration in the 3 months during which they re-
ceived placebo in place of digoxin. Lee et al. (58) found
that 14 of 25 patients with heart failure showed clinical
improvement while receiving digoxin; improvement was
most striking in patients with severe heart failure and a
protodiastolic gallop. The majority of the patients whose
condition did not improvewithdigitalis might not have been
expected to show improvement because they had a normal
left ventricular ejection fraction at rest, were asymptomatic
or had hypertrophic cardiomyopathy.
Other Considerations
Cardiac glycosides are relatively weak inotropic agents
in comparison with catecholamines and the newer inotropic
agents (the bipyridines, amrinone and milrinone) (59). In a
comparison of the inotropic effects of isoproterenol and
ouabain in the normal anesthetized dog (60), isoproterenol
produced a peak increase in contractile force of approxi-
mately 160% of control, compared with an increaseof only
50% resulting fromthe administrationof ouabain. However,
the very fact that glycosides are relatively weak inotropic
agents may make them particularly suitable for long-term
administrationbecause it is possible that prolongedvigorous
stimulation of failing myocardium, that is, so-called "flog-
ging" the failing heart, may be deleterious.
Conclusions
The cardiac glycosides have been used continuously in
clinicalmedicinefor twocenturies. Duringthe past 25years,
a great deal has been learned about the cellular mechanism
of action of these drugs: these appear to result from an
inhibition of sarcolemmal Na+ -K+ adenosine triphospha-
tase, whichcauses an augmentation of intracytoplasmic cal-
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cium concentration, which in tum is responsible for the
stimulation of myocardial contractility. The positive ino-
tropic action is seen in normal as well as in failing hearts,
and has been demonstrated in isolated cardiac muscle, heart-
lung preparations, anesthetized and conscious dogs and hu-
man subjects. Although a positive inotropic action is present
in the normal heart, it is not translated into an augmentation
of a normal cardiac output or reduction of a normal left
ventricular filling pressure. However, substantial hemody-
namic benefits have been demonstrated in the dilated failing
heart. The augmentation of contractility, as shown by an
increase in both dP/dtJP and velocity of myocardial fiber
shortening, is reflected by an improvement in pump per-
formance, with an elevation of depressed cardiac output and
a reduction of elevated ventricular filling pressure. Second-
ary vasodilation occurs, presumably as a consequence of
the withdrawal of sympathetic stimulation characteristic of
heart failure.
Digitalis remains a mainstay ofthe therapyfor congestive
heart failure. Its effects are most prominent in heart failure
associated with atrial fibrillation and a rapid ventricular rate,
but it is also effective in severe heart failure and cardiac
dilation secondary to volume overload, as well as in patients
with a dilated, failing ventricle secondary to hypertension.
Little improvement is observed in patients with left ven-
tricular failure secondary to ventricular outflow tract ob-
struction (aortic or pulmonary stenosis) or in patients with
acute left ventricular failure secondary to myocardial isch-
emia or infarction, or both. When it is administered in
proper doses and for the proper indications, glycoside ther-
apy may be well tolerated by a patient for decades. There-
fore, despite its modest inotropic action and therapeutic
ratio, digitalis remains a useful drug in the therapy of many
patients with chronic congestive heart failure.
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